overview
While significant progress continues to be made in the treatment of certain cancers, others — like gastrointestinal stromal tumors and advanced renal cell carcinoma — have remained more challenging to manage. Even so, new generations of multi-targeted therapies, such as the latest tyrosine kinase inhibitors, are showing enormous promise, not only in treating RCC and GIST, but in teaching oncologists important lessons about the care of other solid tumors, including cancers of the lung, breast and colon.
A faculty of leading oncologists has developed this important educational program to enhance your understanding of the latest state-of-the-art approaches to cancer care. This activity will describe new developments and strategies that have promising implications for managing many solid tumors, emphasizing the newest advances in treating RCC and GIST.
As interest increases in new optionsfor hard-to-treat cancers, this event will bring you up-to-date on the latest evidence-based developments in the field. You'll have the opportunity to get your questions answered by the expert faculty, and earn up to 1 AMA PRA Category 1 Credittm.
View the locations to find a meeting in your area, then register early to ensure a seat. Advance registration is required.